Stephanie Truhlar received her Ph.D. in Chemistry and Chemical Biology from the University of California, San Francisco and completed her post-doctoral training at the University of California, San Diego. In her 14 years at Eli Lilly and Company, she has contributed to the protein engineering of numerous clinical candidates, as well as the development of a proprietary bispecific antibody platform. Over her career, Stephanie’s excellence has been recognized with numerous awards in both the academic and pharmaceutic sectors, published 13 peer-reviewed papers, is a co-inventor on seven patents, and has presented numerous external talks. Stephanie now leads the Computational Sciences and Protein Engineering group in Biotechnology Discovery Research, and she is responsible for the discovery of protein and antibody therapeutics, innovation of core technologies, building new platform technologies, and harnessing predictive modeling capabilities to improve developability, immunogenicity, and pharmacokinetics.
Contemporary biotherapeutics require potent functional activity, exquisite selectivity, minimal modifications during storage and in circulation, desired PK/PD profile, low immunogenicity, and much more. Many strategies exist to engineer protein and antibody therapeutics, but engineering for a single property can disrupt the balance of another one. We have developed new tools that are applied at the earliest stages of antibody discovery, and revisited throughout the discovery and engineering process, to identify and optimize antibodies with desirable properties across myriad dimensions. This Multi-Parameter Optimization takes advantage of experimental data and in silico predictions to identify diverse and desirable antibodies for further engineering or development.